Tamura K - Search Results

1

Deletion of three distinct regions on chromosome 13q in human non-small-cell lung cancer.

Tamura K, Zhang X, Murakami Y, Hirohashi S, Xu HJ, Hu SX, Benedict WF, Sekiya T. Tamura K, et al. Int J Cancer. 1997 Feb 20;74(1):45-9. doi: 10.1002/(sici)1097-0215(19970220)74:1<45::aid-ijc8>3.0.co;2-0. Int J Cancer. 1997. PMID: 9036868 Free article.

2

Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q.

Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, Frischmeyer P, Hunt P, Reeves RH. Murakami Y, et al. Among authors: tamura k. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8153-8. doi: 10.1073/pnas.95.14.8153. Proc Natl Acad Sci U S A. 1998. PMID: 9653156 Free PMC article.

3

Homozygous deletion on the chromosomal region 5q12.3 in human lines of small-cell lung cancers.

Tamura K, Miwa W, Maruyama T, Sekiya T, Murakami Y. Tamura K, et al. J Hum Genet. 2002;47(7):348-54. doi: 10.1007/s100380200048. J Hum Genet. 2002. PMID: 12111368

4

Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.

Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K. Yonesaka K, et al. Among authors: tamura k. Int J Cancer. 2006 Feb 15;118(4):812-20. doi: 10.1002/ijc.21350. Int J Cancer. 2006. PMID: 16108013 Free article.

5

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.

Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M, Nakagawa K. Okabe T, et al. Among authors: tamura k. Mol Cancer Ther. 2008 Mar;7(3):599-606. doi: 10.1158/1535-7163.MCT-07-0567. Mol Cancer Ther. 2008. PMID: 18347146

6

Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

Tamura K, Okamoto I, Ozaki T, Kashii T, Takeda K, Kobayashi M, Matsui K, Shibata T, Kurata T, Nakagawa K, Fukuoka M. Tamura K, et al. Eur J Cancer. 2009 Aug;45(12):2132-7. doi: 10.1016/j.ejca.2009.04.003. Epub 2009 May 4. Eur J Cancer. 2009. PMID: 19409773 Clinical Trial.

7

Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.

Ito T, Kumagai Y, Itano K, Maruyama T, Tamura K, Kawasaki S, Suzuki T, Murakami Y. Ito T, et al. Among authors: tamura k. Biochem Biophys Res Commun. 2019 Apr 9;511(3):544-550. doi: 10.1016/j.bbrc.2019.02.086. Epub 2019 Feb 26. Biochem Biophys Res Commun. 2019. PMID: 30824185

8

Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.

Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Kaneda H, et al. Among authors: tamura k. Lung Cancer. 2004 Nov;46(2):247-54. doi: 10.1016/j.lungcan.2004.04.032. Lung Cancer. 2004. PMID: 15474673

9

Gefitinib in non-small cell lung cancer.

Tamura K, Fukuoka M. Tamura K, et al. Expert Opin Pharmacother. 2005 Jun;6(6):985-93. doi: 10.1517/14656566.6.6.985. Expert Opin Pharmacother. 2005. PMID: 15952926 Review.

10

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K. Okabe T, et al. Among authors: tamura k. Cancer Res. 2007 Mar 1;67(5):2046-53. doi: 10.1158/0008-5472.CAN-06-3339. Cancer Res. 2007. PMID: 17332333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,265 results

Search Page